How to buy argenx stock | $296.02

argenx SE is a biotechnology business based in the US. argenx shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx employs 336 staff and has a trailing 12-month revenue of around 0.00.

argenx stock price (NASDAQ: ARGX)

Use our graph to track the performance of ARGX stocks over time.

argenx shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$296.02
52-week range	$244.98 - $382.15
50-day moving average	$314.74
200-day moving average	$299.99
Wall St. target price	$351.94
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-6.89

Buy argenx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy argenx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

argenx price performance over time

Historical closes compared with the close of $296.02 from 2021-10-20

1 week (2021-10-14)	0.29%
1 month (2021-09-21)	-6.43%
3 months (2021-07-21)	-7.20%
6 months (2021-04-21)	2.31%

1 year (2020-10-21)	15.27%
2 years (2019-10-21)	157.72%
3 years (2018-10-19)	263.66%
5 years (2016-10-17)	N/A

argenx financials

Revenue TTM	$517.8 million
Gross profit TTM	$-270,945,000
Return on assets TTM	-4.36%
Return on equity TTM	-14.14%
Profit margin	-65.15%
Book value	$57.43
Market capitalisation	$15.4 billion

TTM: trailing 12 months

Shorting argenx shares

There are currently 896,000 argenx shares held short by investors – that's known as argenx's "short interest". This figure is 8.6% up from 825,234 last month.

There are a few different ways that this level of interest in shorting argenx shares can be evaluated.

argenx's "short interest ratio" (SIR)

argenx's "short interest ratio" (SIR) is the quantity of argenx shares currently shorted divided by the average quantity of argenx shares traded daily (recently around 198230.08849558). argenx's SIR currently stands at 4.52. In other words for every 100,000 argenx shares traded daily on the market, roughly 4520 shares are currently held short.

However argenx's short interest can also be evaluated against the total number of argenx shares, or, against the total number of tradable argenx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case argenx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 argenx shares in existence, roughly 20 shares are currently held short) or 0.0193% of the tradable shares (for every 100,000 tradable argenx shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against argenx.

Find out more about how you can short argenx stock.

argenx share dividends

We're not expecting argenx to pay a dividend over the next 12 months.

argenx share price volatility

Over the last 12 months, argenx's shares have ranged in value from as little as $244.98 up to $382.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx's is 0.8087. This would suggest that argenx's shares are less volatile than average (for this exchange).

argenx overview

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S. À. R.

Frequently asked questions

What percentage of argenx is owned by institutions?
Currently 57.09% of argenx shares are held by institutions. How many people work for argenx?
Latest data suggests 336 work at argenx. When does the fiscal year end for argenx?
argenx's fiscal year ends in December. Where is argenx based?
argenx's address is: Willemstraat 5, Breda, Netherlands, 4811 AH What is argenx's ISIN number?
argenx's international securities identification number is: US04016X1019 What is argenx's CUSIP number?
argenx's Committee on Uniform Securities Identification Procedures number is: 04016X101